Episode Details
Back to EpisodesManaging Acute Pain with YARAL Pharma's Topical Solutions | Yaral Pharma
Episode 1972
Published 1 year, 8 months ago
Description
Topics: The important role topical patches play in prescription pain management
Key Messages:
Pharmacists play a vital role in supporting patients seeking acute, non-opioid pain relief, and their proactive engagement can ensure personalized and effective pain management solutions.
Clinically proven, medicated patches deliver pain relief directly to the site of pain where it is needed most.
One effective prescription-strength option to consider is YARAL Pharma’s Diclofenac Epolamine Topical Patch 1.3%.
This option may be covered by the patient’s insurance; therefore, patients can access prescription-strength relief while minimizing out-of-pocket costs compared to over-the-counter alternatives.
Product Attributes:
Diclofenac epolamine topical system 1.3%: a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.
Accessible and Affordable
The Authorized Generic of the Flector® (diclofenac epolamine) topical system 1.3%. Patients receive a product identical to the brand, at an affordable price.
Targeted Topical Acute Pain Relief
Low systemic exposure. For a wide variety of patients and pain sites
Fast-acting
Significant pain relief within 4 hours after first application. Sustained pain reduction for 7 days with twice-a-day application
Long Lasting
Delivers NSAID power for 12 hours
Lidocaine Patch 5%: Treatment to help relieve pain associated with post-herpetic neuralgia, a complication from shingles, causing a burning painful skin rash.
Fast Acting
Medicated
Numbing Prescription Relief
Odor Free
Guardrails:
While both Lidocaine Patch 5% and Diclofenac Epolamine Topical System 1.3% may be used for pain, the approved indications differ, therefore we cannot say that diclofenac can be used as an alternative to or substitute for lidocaine, or that Lidocaine Patch 5% (FDA approved only for shingles complications) can be used as an alternative to or substitute for other FDA-approved indications for lidocaine pain-relief products.
We will need to stay on label for each product regarding indication, ISI, etc. and cannot make claims specific to YARAL’s products.
Diclofenac Epolamine Topical System 1.3%
Diclofenac Epolamine Topical System 1.3% - YARAL Pharma Inc.
diclofenac-PI-8-29-23.pdf (yaralpharma.com)
Lidocaine Patch 5%
Lidocaine Patch 5% - YARAL Pharma Inc.
PI_Lidocaine-13851.pdf (yaralpharma.com)
Ensure products are not positioned for chronic pain.
We cannot make comparisons that YARAL’s products can be used as an alternative to opioids because the indications for use and safety profiles are different, and there is no head-to-head study at this time directly comparing the safety/efficacy of YARAL’s products to opioids for YARAL’s FDA-approved uses.
We cannot make comparative claims to OTC pain relief products or suggest alternatives because the safety profiles differ and the approved indications for use may differ across various products.
Must focus only on monadic (non-comparative) claims for YARAL’s products.
Must include fair balance with safety information, including the «major statement« of risks for products discussed.
Questions/Topics:
Introduction:
Can you share a bit about your background and experience in pain management as a pharmacist?
How did you become interested in non-opioid pain management?
Can you speak about the evolution of pain management?
Movement toward topical pain treatment options
How topical patches play a role in pain management <
Key Messages:
Pharmacists play a vital role in supporting patients seeking acute, non-opioid pain relief, and their proactive engagement can ensure personalized and effective pain management solutions.
Clinically proven, medicated patches deliver pain relief directly to the site of pain where it is needed most.
One effective prescription-strength option to consider is YARAL Pharma’s Diclofenac Epolamine Topical Patch 1.3%.
This option may be covered by the patient’s insurance; therefore, patients can access prescription-strength relief while minimizing out-of-pocket costs compared to over-the-counter alternatives.
Product Attributes:
Diclofenac epolamine topical system 1.3%: a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.
Accessible and Affordable
The Authorized Generic of the Flector® (diclofenac epolamine) topical system 1.3%. Patients receive a product identical to the brand, at an affordable price.
Targeted Topical Acute Pain Relief
Low systemic exposure. For a wide variety of patients and pain sites
Fast-acting
Significant pain relief within 4 hours after first application. Sustained pain reduction for 7 days with twice-a-day application
Long Lasting
Delivers NSAID power for 12 hours
Lidocaine Patch 5%: Treatment to help relieve pain associated with post-herpetic neuralgia, a complication from shingles, causing a burning painful skin rash.
Fast Acting
Medicated
Numbing Prescription Relief
Odor Free
Guardrails:
While both Lidocaine Patch 5% and Diclofenac Epolamine Topical System 1.3% may be used for pain, the approved indications differ, therefore we cannot say that diclofenac can be used as an alternative to or substitute for lidocaine, or that Lidocaine Patch 5% (FDA approved only for shingles complications) can be used as an alternative to or substitute for other FDA-approved indications for lidocaine pain-relief products.
We will need to stay on label for each product regarding indication, ISI, etc. and cannot make claims specific to YARAL’s products.
Diclofenac Epolamine Topical System 1.3%
Diclofenac Epolamine Topical System 1.3% - YARAL Pharma Inc.
diclofenac-PI-8-29-23.pdf (yaralpharma.com)
Lidocaine Patch 5%
Lidocaine Patch 5% - YARAL Pharma Inc.
PI_Lidocaine-13851.pdf (yaralpharma.com)
Ensure products are not positioned for chronic pain.
We cannot make comparisons that YARAL’s products can be used as an alternative to opioids because the indications for use and safety profiles are different, and there is no head-to-head study at this time directly comparing the safety/efficacy of YARAL’s products to opioids for YARAL’s FDA-approved uses.
We cannot make comparative claims to OTC pain relief products or suggest alternatives because the safety profiles differ and the approved indications for use may differ across various products.
Must focus only on monadic (non-comparative) claims for YARAL’s products.
Must include fair balance with safety information, including the «major statement« of risks for products discussed.
Questions/Topics:
Introduction:
Can you share a bit about your background and experience in pain management as a pharmacist?
How did you become interested in non-opioid pain management?
Can you speak about the evolution of pain management?
Movement toward topical pain treatment options
How topical patches play a role in pain management <